Atipamezole

Overview

Atipamezole (Antisedan®, Revertidine®) is a selective alpha-2-adrenergic antagonist used in small animal practice as a pharmacologic reversal agent for alpha-2-adrenergic agonists, most notably dexmedetomidine and medetomidine. It is primarily used in dogs and cats to rapidly reverse sedation and associated cardiovascular effects following diagnostic or surgical procedures.

In dogs, atipamezole is FDA-approved for reversal of dexmedetomidine and medetomidine–induced sedation. In cats, its use is extra-label but common in clinical settings for reversing medetomidine- or dexmedetomidine-based sedation and anesthetic protocols.

Reversal with atipamezole can be rapid and pronounced, often restoring consciousness, motor activity, and cardiovascular parameters within minutes after intramuscular administration. Because alpha-2 agonist–induced analgesia is also reversed, patients may experience sudden return of pain perception and should be closely monitored.

The duration of action of atipamezole may be shorter than that of the alpha-2 agonist being reversed. As a result, resedation can occur, and repeat dosing may be required in some patients, particularly when long-acting or high doses of alpha-2 agonists were administered.

Atipamezole does not provide analgesia or sedation on its own and should be used judiciously, with appropriate patient restraint and environmental control, to prevent injury to the patient or personnel during recovery.

Indications

Atipamezole is used in dogs and cats as a specific pharmacologic antagonist to reverse the sedative, cardiovascular, and analgesic effects of alpha-2-adrenergic agonists. Its use allows more rapid recovery, improved patient monitoring, and safer discharge following sedation or anesthesia.

• Reversal of dexmedetomidine sedation (dogs):
  FDA-approved for reversing the sedative and cardiovascular effects of dexmedetomidine administered for diagnostic, procedural, or perioperative sedation.
• Reversal of medetomidine sedation (dogs and cats):
  Commonly used to antagonize medetomidine-induced sedation, bradycardia, and hypotension after procedures or imaging.
• Recovery facilitation after short procedures:
  Used to hasten recovery following minor surgical or diagnostic procedures where prolonged sedation is undesirable.
• Management of excessive or prolonged alpha-2 agonist effects:
  Administered when sedation, bradycardia, or cardiovascular depression is deeper or longer lasting than intended.
• Adjunctive treatment of alpha-2-agonist toxicosis:
  Used in dogs and cats exposed to toxic or accidental overdoses of alpha-2-adrenergic agonists (eg, dexmedetomidine, medetomidine, amitraz).
• Emergency reversal during anesthesia or resuscitation:
  May be administered as part of advanced life support protocols to reverse alpha-2–mediated cardiovascular depression when clinically indicated.

Dosage (Reference)

Dog

In dogs, atipamezole is FDA-approved for reversal of dexmedetomidine
and medetomidine–induced sedation. Dosing is based on body surface
area for labeled use; extra-label dosing based on body weight is
also used in specific clinical situations.

Cat

In cats, atipamezole is used extra-label for reversal of medetomidine-
or dexmedetomidine–based sedation protocols. Lower doses and careful
monitoring are recommended due to cardiovascular sensitivity.

Warnings & Precautions

Atipamezole is a potent and fast-acting alpha-2–adrenergic antagonist. Its primary risks are related to abrupt reversal of sedation and analgesia, as well as cardiovascular and behavioral effects during recovery.

• Rapid arousal and excitation:
  Reversal can occur suddenly, and animals may become anxious, vocal, disoriented, or aggressive. Protect personnel and prevent self-injury during recovery.
• Loss of analgesia:
  Atipamezole reverses both sedation and analgesia produced by alpha-2 agonists. Painful patients should receive alternative analgesia (eg, opioids, local blocks) before or immediately after reversal.
• Resedation risk:
  The duration of atipamezole may be shorter than that of the alpha-2 agonist. Recurrence of sedation and bradycardia can occur, and repeat dosing may be required.
• Cardiovascular effects:
  Transient hypotension followed by hypertension, tachycardia, and increased respiratory rate may be observed. Severe arterial hypotension has been reported in cats.
• Use after anesthesia:
  When alpha-2 agonists are used with ketamine or tiletamine/zolazepam, reversal should generally be delayed 30–60 minutes to allow dissociative agents to be metabolized and avoid rough recoveries.
• IV administration:
  Routine reversal should be performed IM. IV administration is reserved for emergency situations (eg, CPR). In some species (eg, reptiles), IV administration may cause profound hypotension and should be avoided.
• Behavioral safety:
  Animals may awaken suddenly with intact motor function but altered awareness. Prevent falls and ensure a quiet, controlled environment during recovery.
• Hypersensitivity:
  Contraindicated in patients with known hypersensitivity to atipamezole or formulation components.
• Pregnancy and lactation:
  Safety has not been established. Use only if the expected maternal benefit clearly outweighs potential fetal or neonatal risk.

Drug Interactions

Clinically relevant drug interactions with atipamezole are primarily related to its antagonism of alpha-2–adrenergic receptors and its secondary cardiovascular and CNS effects. Most interactions are expected and intentional when atipamezole is used as a reversal agent.

• Alpha-2–adrenergic agonists (eg, dexmedetomidine, medetomidine, xylazine, amitraz):
  Atipamezole competitively antagonizes the sedative, analgesic, cardiovascular, and toxic effects of these drugs. This interaction is intentional when used for reversal or antidotal therapy.
• Opioids:
  Atipamezole does not reverse opioid-induced analgesia or respiratory effects. Opioids are commonly used concurrently or after reversal to maintain analgesia once alpha-2–mediated analgesia is lost.
• Ketamine or tiletamine/zolazepam:
  Reversing alpha-2 agonists too early may result in excitation, dysphoria, or rough recovery due to unopposed dissociative effects. Delay reversal (generally 30–60 minutes) after induction when these agents are used.
• Alpha-1–adrenergic antagonists (eg, prazosin):
  Atipamezole is relatively selective for alpha-2 receptors but may partially block alpha-1 receptors at higher doses, potentially reducing the therapeutic effects of alpha-1 antagonists.
• Other sedatives and anesthetics:
  Atipamezole does not reverse CNS depression caused by drugs outside the alpha-2 class (eg, benzodiazepines, inhalant anesthetics). Residual sedation may persist from these agents.
• Cardioactive drugs:
  Abrupt increases in heart rate and blood pressure after reversal may interact with concurrent cardiovascular medications; monitoring is recommended in patients receiving antiarrhythmic or antihypertensive therapy.

Side Effects & Overdose

Side Effects

Adverse effects associated with atipamezole are generally related to rapid reversal of alpha-2–adrenergic agonist effects and sudden arousal from sedation and analgesia. Most effects are transient and dose dependent.

• Gastrointestinal signs:
  Vomiting, diarrhea, and hypersalivation may occur shortly after administration, particularly in dogs.
• CNS stimulation:
  Transient excitation, apprehensiveness, vocalization, restlessness, or tremors may be observed during recovery.
• Loss of analgesia:
  Abrupt reversal of alpha-2–mediated analgesia may result in signs of pain if alternative analgesics are not provided.
• Cardiovascular effects:
  Transient changes in blood pressure (hypotension followed by hypertension), increased heart rate, and increased respiratory rate may occur. Severe arterial hypotension has been reported in cats.
• Injection site reactions:
  Mild discomfort or localized muscle irritation may occur following IM administration.

Overdose

Atipamezole has a relatively wide margin of safety in dogs and cats. Clinical signs of overdose primarily reflect exaggerated pharmacologic effects.

• Clinical signs:
  Panting, marked excitation, trembling, vomiting, soft or liquid feces, peripheral vasodilation (eg, injected sclera), and transient behavioral changes.
• Laboratory changes:
  Transient increases in serum ALT and creatine kinase activity have been reported following very high doses.
• Management:
  Specific antidotal therapy is usually not required. Treatment is supportive and includes observation, minimizing stimulation, maintaining a quiet environment, and monitoring cardiovascular parameters.

Key Notes

Practical clinical pearls that help ensure safe and effective use of atipamezole in dogs and cats when reversing alpha-2–adrenergic agonists:

• Purpose-built reversal:
  Atipamezole is specifically designed to reverse alpha-2 agonists and should not be expected to counteract sedation from other drug classes.
• Predictable response:
  Most dogs and cats show noticeable reversal within minutes after IM administration, making it useful for shortening recovery and discharge times.
• Timing matters:
  Delaying reversal after combination anesthesia improves the quality of recovery and reduces dysphoria.
• Dose matching principle:
  In cats, reversal dosing is often based on the volume or relative dose of the alpha-2 agonist administered rather than strict weight-based calculations.
• Environment control:
  A calm, quiet recovery area reduces excitement and improves patient comfort after rapid awakening.
• Analgesia planning:
  Atipamezole should be considered part of an analgesic plan, not a standalone step, especially after painful procedures.
• Monitoring priority:
  Continuous observation during early recovery is essential to identify resedation, cardiovascular changes, or behavioral reactions.
• Professional use only:
  Administration should remain limited to trained veterinary personnel due to the rapid and sometimes dramatic physiologic effects.